Erratum: Risk factors for prognosis in patients with severely decreased GFR (Kidney International Reports (2018) 3 (625-637) DOI: 10.1016/j.ekir.2018.01.002 PII: S246802491830007X)

Maccabi Health System; Multifactorial Approach and Superior Treatment Efficacy in Renal Patients with the Aid of a Nurse Practitioner (MASTERPLAN); Modification of Diet in Renal Disease Study (MDRD); Nanjing CKD Network Cohort Study (Nanjing CKD); NephroTest Study; National RenalHealthcareProgram-Uruguay (NRHP-URU); New Zealand Diabetes Cohort Study (NZDCS); Parcours de Soins des Personnes Agées (PSPA); Primary-Secondary Care Partnership to Prevent Adverse Outcomes in Chronic Kidney Disease (PSP CKD); Racial and Cardiovascular Risk Anomalies in CKD Cohort (RCAV); Reduction of Endpoints in Non-insulin Dependent Diabetes Mellitus with the Angiotensin II Antagonist Losartan (RENAAL); Stockholm CREAtinine Measurements Cohort (SCREAM); Second Manifestations of ARTerial Disease Study (SMART); Swedish Renal Registry CKD Cohort (SRR CKD); Sunnybrook Cohort; West of Scotl and CKD Study; CKD Prognosis Consortium Steering Committee; CKD Prognosis Consortium Data Coordinating Center; Kidney Disease Improving Global Outcomes (KDIGO) Controversies Conference on Prognosis and Optimal Management of Patients with Advanced CKD; Chronic Kidney Disease (CKD) Prognosis Consortium; CKD Prognosis Consortium investigators/collaborators; African American Study of Kidney Disease and Hypertension (AASK); British Columbia CKD Study (BC CKD); Canadian Study of Prediction of Death, Dialysis and Interim Cardiovascular Events (CanPREDDICT); Cleveland Clinic CKD Registry Study (CCF); Chronic Renal Impairment in Birmingham (CRIB); Chronic Renal Insufficiency Cohort Study (CRIC); Chronic Renal Insufficiency Standards Implementation Study (CRISIS); German Chronic Kidney Disease Study (GCKD); Geisinger Health System; Grampian Laboratory Outcomes, Morbidity and Mortality Studies - 2 (GLOMMS2); Gonryo Study; Hong Kong CKD Studies

doi:10.1016/j.ekir.2018.08.009

Erratum: Risk factors for prognosis in patients with severely decreased GFR (Kidney International Reports (2018) 3 (625-637) DOI: 10.1016/j.ekir.2018.01.002 PII: S246802491830007X)

Maccabi Health System, Multifactorial Approach and Superior Treatment Efficacy in Renal Patients with the Aid of a Nurse Practitioner (MASTERPLAN), Modification of Diet in Renal Disease Study (MDRD), Nanjing CKD Network Cohort Study (Nanjing CKD), NephroTest Study, National RenalHealthcareProgram-Uruguay (NRHP-URU), New Zealand Diabetes Cohort Study (NZDCS), Parcours de Soins des Personnes Agées (PSPA), Primary-Secondary Care Partnership to Prevent Adverse Outcomes in Chronic Kidney Disease (PSP CKD), Racial and Cardiovascular Risk Anomalies in CKD Cohort (RCAV), Reduction of Endpoints in Non-insulin Dependent Diabetes Mellitus with the Angiotensin II Antagonist Losartan (RENAAL), Stockholm CREAtinine Measurements Cohort (SCREAM), Second Manifestations of ARTerial Disease Study (SMART), Swedish Renal Registry CKD Cohort (SRR CKD), Sunnybrook Cohort, West of Scotl and CKD Study, CKD Prognosis Consortium Steering Committee, CKD Prognosis Consortium Data Coordinating Center, Kidney Disease Improving Global Outcomes (KDIGO) Controversies Conference on Prognosis and Optimal Management of Patients with Advanced CKD, Chronic Kidney Disease (CKD) Prognosis ConsortiumCKD Prognosis Consortium investigators/collaborators, African American Study of Kidney Disease and Hypertension (AASK), British Columbia CKD Study (BC CKD), Canadian Study of Prediction of Death, Dialysis and Interim Cardiovascular Events (CanPREDDICT), Cleveland Clinic CKD Registry Study (CCF), Chronic Renal Impairment in Birmingham (CRIB), Chronic Renal Insufficiency Cohort Study (CRIC), Chronic Renal Insufficiency Standards Implementation Study (CRISIS), German Chronic Kidney Disease Study (GCKD), Geisinger Health System, Grampian Laboratory Outcomes, Morbidity and Mortality Studies - 2 (GLOMMS2), Gonryo Study, Hong Kong CKD Studies

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

The Chronic Kidney Disease (CKD) Prognosis Consortium is a collaborative author of the above-mentioned article. The CKD Prognosis Consortium investigators/collaborators are as follows: • African American Study of Kidney Disease and Hypertension (AASK): Brad Astor, Lawrence J. Appel; British Columbia CKD Study (BC CKD): Adeera Levin, Ognjenka Djurdjev; Canadian Study of Prediction of Death, Dialysis and Interim Cardiovascular Events (CanPREDDICT): Adeera Levin, Mila Tang, Ognjenka Djurdjev; Cleveland Clinic CKD Registry Study (CCF): Sankar D. Navaneethan, Stacey E. Jolly, Jesse D. Schold, Joseph V. Nally Jr; Chronic Renal Impairment in Birmingham (CRIB): David C. Wheeler, Jonathan Emberson, John Townend, Martin Landray; Chronic Renal Insufficiency Cohort Study (CRIC): Harold I. Feldman, Chi-yuan Hsu, James P. Lash, Lawrence J. Appel; Chronic Renal Insufficiency Standards Implementation Study (CRISIS): Philip A. Kalra, James P. Ritchie, Raman Maharajan, Helen Alderson, Beverly Lane; German Chronic Kidney Disease Study (GCKD): Kai-Uwe Eckardt, Markus P. Schneider, Anna Köttgen, Florian Kronenberg, Barbara Bärthlein; Geisinger Health System: Alex R. Chang, Jamie A. Green, H. Lester Kirchner, Kevin Ho; Grampian Laboratory Outcomes, Morbidity and Mortality Studies – 2 (GLOMMS2): Angharad Marks, Corri Black, Gordon J. Prescott, Nick Fluck; Gonryo Study: Masaaki Nakayama, Mariko Miyazaki, Tae Yamamoto, Gen Yamada; Hong Kong CKD Studies: Angela Yee-Moon Wang, Sharon Cheung, Sharon Wong, Jessie Chu, Henry Wu; Maccabi Health System: Varda Shalev, Gabriel Chodick; Multifactorial Approach and Superior Treatment Efficacy in Renal Patients with the Aid of a Nurse Practitioner (MASTERPLAN): Peter J. Blankestijn, Jack F.M. Wetzels, Arjan D. van Zuilen, Jan A. van den Brand; Modification of Diet in Renal Disease Study (MDRD): Andrew S. Levey, Lesley A. Inker, Mark J. Sarnak, Hocine Tighiouart; Nanjing CKD Network Cohort Study (Nanjing CKD): Haitao Zhang; NephroTest Study: Benedicte Stengel; National Renal Healthcare Program – Uruguay (NRHP-URU): Pablo G. Rios, Nelson Mazzuchi, Liliana Gadola, Verónica Lamadrid, Laura Sola; New Zealand Diabetes Cohort Study (NZDCS): John F. Collins, C. Raina Elley, Timothy Kenealy; Parcours de Soins des Personnes Agées (PSPA): Olivier Moranne, Cecile Couchoud, Cecile Vigneau; Primary-Secondary Care Partnership to Prevent Adverse Outcomes in Chronic Kidney Disease (PSP CKD): Nigel J. Brunskill, Rupert W. Major, David Shepherd, James F. Medcalf; Racial and Cardiovascular Risk Anomalies in CKD Cohort (RCAV): Csaba P. Kovesdy, Kamyar Kalantar-Zadeh, Miklos Z. Molnar, Keiichi Sumida, Praveen K. Potukuchi; Reduction of Endpoints in Non-insulin Dependent Diabetes Mellitus with the Angiotensin II Antagonist Losartan (RENAAL): Hiddo J.L. Heerspink, Dick de Zeeuw, Barry Brenner; Stockholm CREAtinine Measurements Cohort (SCREAM): Juan Jesus Carrero, Peter Barany, Abdul Rashid Qureshi, Carl-Gustaf Elinder; Second Manifestations of ARTerial Disease Study (SMART): Frank L.J. Visseren, Yolanda van der Graaf; Swedish Renal Registry CKD Cohort (SRR CKD): Marie Evans, Maria Stendahl, Staffan Schön, Mårten Segelmark, Karl-Göran Prütz; Sunnybrook Cohort: David M. Naimark, Navdeep Tangri; West of Scotland CKD Study: Patrick B. Mark, Jamie P. Traynor, Colin C. Geddes, Peter C. Thomson.• CKD Prognosis Consortium Steering Committee: Alex R. Chang, Josef Coresh (Chair), Ron T. Gansevoort, Morgan E. Grams, Anna Köttgen, Andrew S. Levey, Kunihiro Matsushita, Mark Woodward, Luxia Zhang.• CKD Prognosis Consortium Data Coordinating Center: Shoshana H. Ballew (Assistant Project Director), Jingsha Chen (Programmer), Josef Coresh (Principal Investigator), Morgan E. Grams (Director of Nephrology Initiatives), Lucia Kwak (Programmer), Kunihiro Matsushita (Director), Yingying Sang (Lead Programmer), Aditya Surapaneni (Programmer), Mark Woodward (Senior Statistician).• Kidney Disease Improving Global Outcomes (KDIGO) Controversies Conference on Prognosis and Optimal Management of Patients with Advanced CKD: Kai-Uwe Eckardt (Conference Co-Chair), Brenda R. Hemmelgarn (Conference Co-Chair), David C. Wheeler (KDIGO Co-Chair), Wolfgang C. Winkelmayer (KDIGO Co-Chair), John Davis (CEO), Danielle Green (Managing Director), Michael Cheung (Chief Scientific Officer), Tanya Green (Communications Director), Melissa McMahan (Programs Director).

Original language	English (US)
Pages (from-to)	1506
Number of pages	1
Journal	Kidney International Reports
Volume	3
Issue number	6
DOIs	https://doi.org/10.1016/j.ekir.2018.08.009
State	Published - Nov 1 2018

ASJC Scopus subject areas

Nephrology

Access to Document

10.1016/j.ekir.2018.08.009

Cite this

Maccabi Health System, Multifactorial Approach and Superior Treatment Efficacy in Renal Patients with the Aid of a Nurse Practitioner (MASTERPLAN), Modification of Diet in Renal Disease Study (MDRD), Nanjing CKD Network Cohort Study (Nanjing CKD), NephroTest Study, National RenalHealthcareProgram-Uruguay (NRHP-URU), New Zealand Diabetes Cohort Study (NZDCS), Parcours de Soins des Personnes Agées (PSPA), Primary-Secondary Care Partnership to Prevent Adverse Outcomes in Chronic Kidney Disease (PSP CKD), Racial and Cardiovascular Risk Anomalies in CKD Cohort (RCAV), Reduction of Endpoints in Non-insulin Dependent Diabetes Mellitus with the Angiotensin II Antagonist Losartan (RENAAL), Stockholm CREAtinine Measurements Cohort (SCREAM), Second Manifestations of ARTerial Disease Study (SMART), Swedish Renal Registry CKD Cohort (SRR CKD), Sunnybrook Cohort, West of Scotl and CKD Study, CKD Prognosis Consortium Steering Committee, CKD Prognosis Consortium Data Coordinating Center, Kidney Disease Improving Global Outcomes (KDIGO) Controversies Conference on Prognosis and Optimal Management of Patients with Advanced CKD, ... Hong Kong CKD Studies (2018). Erratum: Risk factors for prognosis in patients with severely decreased GFR (Kidney International Reports (2018) 3 (625-637) DOI: 10.1016/j.ekir.2018.01.002 PII: S246802491830007X). Kidney International Reports, 3(6), 1506. https://doi.org/10.1016/j.ekir.2018.08.009

Erratum: Risk factors for prognosis in patients with severely decreased GFR (Kidney International Reports (2018) 3 (625-637) DOI: 10.1016/j.ekir.2018.01.002 PII: S246802491830007X). / Maccabi Health System; Multifactorial Approach and Superior Treatment Efficacy in Renal Patients with the Aid of a Nurse Practitioner (MASTERPLAN); Modification of Diet in Renal Disease Study (MDRD) et al.
In: Kidney International Reports, Vol. 3, No. 6, 01.11.2018, p. 1506.

Research output: Contribution to journal › Comment/debate › peer-review

Maccabi Health System, Multifactorial Approach and Superior Treatment Efficacy in Renal Patients with the Aid of a Nurse Practitioner (MASTERPLAN), Modification of Diet in Renal Disease Study (MDRD), Nanjing CKD Network Cohort Study (Nanjing CKD), NephroTest Study, National RenalHealthcareProgram-Uruguay (NRHP-URU), New Zealand Diabetes Cohort Study (NZDCS), Parcours de Soins des Personnes Agées (PSPA), Primary-Secondary Care Partnership to Prevent Adverse Outcomes in Chronic Kidney Disease (PSP CKD), Racial and Cardiovascular Risk Anomalies in CKD Cohort (RCAV), Reduction of Endpoints in Non-insulin Dependent Diabetes Mellitus with the Angiotensin II Antagonist Losartan (RENAAL), Stockholm CREAtinine Measurements Cohort (SCREAM), Second Manifestations of ARTerial Disease Study (SMART), Swedish Renal Registry CKD Cohort (SRR CKD), Sunnybrook Cohort, West of Scotl and CKD Study, CKD Prognosis Consortium Steering Committee, CKD Prognosis Consortium Data Coordinating Center, Kidney Disease Improving Global Outcomes (KDIGO) Controversies Conference on Prognosis and Optimal Management of Patients with Advanced CKD, Chronic Kidney Disease (CKD) Prognosis Consortium, CKD Prognosis Consortium investigators/collaborators, African American Study of Kidney Disease and Hypertension (AASK), British Columbia CKD Study (BC CKD), Canadian Study of Prediction of Death, Dialysis and Interim Cardiovascular Events (CanPREDDICT), Cleveland Clinic CKD Registry Study (CCF), Chronic Renal Impairment in Birmingham (CRIB), Chronic Renal Insufficiency Cohort Study (CRIC), Chronic Renal Insufficiency Standards Implementation Study (CRISIS), German Chronic Kidney Disease Study (GCKD), Geisinger Health System, Grampian Laboratory Outcomes, Morbidity and Mortality Studies - 2 (GLOMMS2), Gonryo Study & Hong Kong CKD Studies 2018, 'Erratum: Risk factors for prognosis in patients with severely decreased GFR (Kidney International Reports (2018) 3 (625-637) DOI: 10.1016/j.ekir.2018.01.002 PII: S246802491830007X)', Kidney International Reports, vol. 3, no. 6, pp. 1506. https://doi.org/10.1016/j.ekir.2018.08.009

Maccabi Health System, Multifactorial Approach and Superior Treatment Efficacy in Renal Patients with the Aid of a Nurse Practitioner (MASTERPLAN), Modification of Diet in Renal Disease Study (MDRD), Nanjing CKD Network Cohort Study (Nanjing CKD), NephroTest Study, National RenalHealthcareProgram-Uruguay (NRHP-URU) et al. Erratum: Risk factors for prognosis in patients with severely decreased GFR (Kidney International Reports (2018) 3 (625-637) DOI: 10.1016/j.ekir.2018.01.002 PII: S246802491830007X). Kidney International Reports. 2018 Nov 1;3(6):1506. doi: 10.1016/j.ekir.2018.08.009

Maccabi Health System ; Multifactorial Approach and Superior Treatment Efficacy in Renal Patients with the Aid of a Nurse Practitioner (MASTERPLAN) ; Modification of Diet in Renal Disease Study (MDRD) et al. / Erratum : Risk factors for prognosis in patients with severely decreased GFR (Kidney International Reports (2018) 3 (625-637) DOI: 10.1016/j.ekir.2018.01.002 PII: S246802491830007X). In: Kidney International Reports. 2018 ; Vol. 3, No. 6. pp. 1506.

@article{42b46f67e50a45129252f9985f960aeb,

title = "Erratum: Risk factors for prognosis in patients with severely decreased GFR (Kidney International Reports (2018) 3 (625-637) DOI: 10.1016/j.ekir.2018.01.002 PII: S246802491830007X)",

abstract = "The Chronic Kidney Disease (CKD) Prognosis Consortium is a collaborative author of the above-mentioned article. The CKD Prognosis Consortium investigators/collaborators are as follows: • African American Study of Kidney Disease and Hypertension (AASK): Brad Astor, Lawrence J. Appel; British Columbia CKD Study (BC CKD): Adeera Levin, Ognjenka Djurdjev; Canadian Study of Prediction of Death, Dialysis and Interim Cardiovascular Events (CanPREDDICT): Adeera Levin, Mila Tang, Ognjenka Djurdjev; Cleveland Clinic CKD Registry Study (CCF): Sankar D. Navaneethan, Stacey E. Jolly, Jesse D. Schold, Joseph V. Nally Jr; Chronic Renal Impairment in Birmingham (CRIB): David C. Wheeler, Jonathan Emberson, John Townend, Martin Landray; Chronic Renal Insufficiency Cohort Study (CRIC): Harold I. Feldman, Chi-yuan Hsu, James P. Lash, Lawrence J. Appel; Chronic Renal Insufficiency Standards Implementation Study (CRISIS): Philip A. Kalra, James P. Ritchie, Raman Maharajan, Helen Alderson, Beverly Lane; German Chronic Kidney Disease Study (GCKD): Kai-Uwe Eckardt, Markus P. Schneider, Anna K{\"o}ttgen, Florian Kronenberg, Barbara B{\"a}rthlein; Geisinger Health System: Alex R. Chang, Jamie A. Green, H. Lester Kirchner, Kevin Ho; Grampian Laboratory Outcomes, Morbidity and Mortality Studies – 2 (GLOMMS2): Angharad Marks, Corri Black, Gordon J. Prescott, Nick Fluck; Gonryo Study: Masaaki Nakayama, Mariko Miyazaki, Tae Yamamoto, Gen Yamada; Hong Kong CKD Studies: Angela Yee-Moon Wang, Sharon Cheung, Sharon Wong, Jessie Chu, Henry Wu; Maccabi Health System: Varda Shalev, Gabriel Chodick; Multifactorial Approach and Superior Treatment Efficacy in Renal Patients with the Aid of a Nurse Practitioner (MASTERPLAN): Peter J. Blankestijn, Jack F.M. Wetzels, Arjan D. van Zuilen, Jan A. van den Brand; Modification of Diet in Renal Disease Study (MDRD): Andrew S. Levey, Lesley A. Inker, Mark J. Sarnak, Hocine Tighiouart; Nanjing CKD Network Cohort Study (Nanjing CKD): Haitao Zhang; NephroTest Study: Benedicte Stengel; National Renal Healthcare Program – Uruguay (NRHP-URU): Pablo G. Rios, Nelson Mazzuchi, Liliana Gadola, Ver{\'o}nica Lamadrid, Laura Sola; New Zealand Diabetes Cohort Study (NZDCS): John F. Collins, C. Raina Elley, Timothy Kenealy; Parcours de Soins des Personnes Ag{\'e}es (PSPA): Olivier Moranne, Cecile Couchoud, Cecile Vigneau; Primary-Secondary Care Partnership to Prevent Adverse Outcomes in Chronic Kidney Disease (PSP CKD): Nigel J. Brunskill, Rupert W. Major, David Shepherd, James F. Medcalf; Racial and Cardiovascular Risk Anomalies in CKD Cohort (RCAV): Csaba P. Kovesdy, Kamyar Kalantar-Zadeh, Miklos Z. Molnar, Keiichi Sumida, Praveen K. Potukuchi; Reduction of Endpoints in Non-insulin Dependent Diabetes Mellitus with the Angiotensin II Antagonist Losartan (RENAAL): Hiddo J.L. Heerspink, Dick de Zeeuw, Barry Brenner; Stockholm CREAtinine Measurements Cohort (SCREAM): Juan Jesus Carrero, Peter Barany, Abdul Rashid Qureshi, Carl-Gustaf Elinder; Second Manifestations of ARTerial Disease Study (SMART): Frank L.J. Visseren, Yolanda van der Graaf; Swedish Renal Registry CKD Cohort (SRR CKD): Marie Evans, Maria Stendahl, Staffan Sch{\"o}n, M{\aa}rten Segelmark, Karl-G{\"o}ran Pr{\"u}tz; Sunnybrook Cohort: David M. Naimark, Navdeep Tangri; West of Scotland CKD Study: Patrick B. Mark, Jamie P. Traynor, Colin C. Geddes, Peter C. Thomson.• CKD Prognosis Consortium Steering Committee: Alex R. Chang, Josef Coresh (Chair), Ron T. Gansevoort, Morgan E. Grams, Anna K{\"o}ttgen, Andrew S. Levey, Kunihiro Matsushita, Mark Woodward, Luxia Zhang.• CKD Prognosis Consortium Data Coordinating Center: Shoshana H. Ballew (Assistant Project Director), Jingsha Chen (Programmer), Josef Coresh (Principal Investigator), Morgan E. Grams (Director of Nephrology Initiatives), Lucia Kwak (Programmer), Kunihiro Matsushita (Director), Yingying Sang (Lead Programmer), Aditya Surapaneni (Programmer), Mark Woodward (Senior Statistician).• Kidney Disease Improving Global Outcomes (KDIGO) Controversies Conference on Prognosis and Optimal Management of Patients with Advanced CKD: Kai-Uwe Eckardt (Conference Co-Chair), Brenda R. Hemmelgarn (Conference Co-Chair), David C. Wheeler (KDIGO Co-Chair), Wolfgang C. Winkelmayer (KDIGO Co-Chair), John Davis (CEO), Danielle Green (Managing Director), Michael Cheung (Chief Scientific Officer), Tanya Green (Communications Director), Melissa McMahan (Programs Director).",

author = "{Maccabi Health System} and {Multifactorial Approach and Superior Treatment Efficacy in Renal Patients with the Aid of a Nurse Practitioner (MASTERPLAN)} and {Modification of Diet in Renal Disease Study (MDRD)} and {Nanjing CKD Network Cohort Study (Nanjing CKD)} and {NephroTest Study} and {National RenalHealthcareProgram-Uruguay (NRHP-URU)} and {New Zealand Diabetes Cohort Study (NZDCS)} and {Parcours de Soins des Personnes Ag{\'e}es (PSPA)} and {Primary-Secondary Care Partnership to Prevent Adverse Outcomes in Chronic Kidney Disease (PSP CKD)} and {Racial and Cardiovascular Risk Anomalies in CKD Cohort (RCAV)} and {Reduction of Endpoints in Non-insulin Dependent Diabetes Mellitus with the Angiotensin II Antagonist Losartan (RENAAL)} and {Stockholm CREAtinine Measurements Cohort (SCREAM)} and {Second Manifestations of ARTerial Disease Study (SMART)} and {Swedish Renal Registry CKD Cohort (SRR CKD)} and {Sunnybrook Cohort} and {West of Scotl and CKD Study} and {CKD Prognosis Consortium Steering Committee} and {CKD Prognosis Consortium Data Coordinating Center} and {Kidney Disease Improving Global Outcomes (KDIGO) Controversies Conference on Prognosis and Optimal Management of Patients with Advanced CKD} and {Chronic Kidney Disease (CKD) Prognosis Consortium} and {CKD Prognosis Consortium investigators/collaborators} and {African American Study of Kidney Disease and Hypertension (AASK)} and {British Columbia CKD Study (BC CKD)} and {Canadian Study of Prediction of Death, Dialysis and Interim Cardiovascular Events (CanPREDDICT)} and {Cleveland Clinic CKD Registry Study (CCF)} and {Chronic Renal Impairment in Birmingham (CRIB)} and {Chronic Renal Insufficiency Cohort Study (CRIC)} and {Chronic Renal Insufficiency Standards Implementation Study (CRISIS)} and {German Chronic Kidney Disease Study (GCKD)} and {Geisinger Health System} and {Grampian Laboratory Outcomes, Morbidity and Mortality Studies - 2 (GLOMMS2)} and {Gonryo Study} and {Hong Kong CKD Studies} and Brad Astor and Appel, {Lawrence J.} and Adeera Levin and Ognjenka Djurdjev and Mila Tang and Navaneethan, {Sankar D.} and Jolly, {Stacey E.} and Schold, {Jesse D.} and Nally, {Joseph V.} and Wheeler, {David C.} and Jonathan Emberson and John Townend and Martin Landray and Feldman, {Harold I.} and Hsu, {Chi Yuan} and Lash, {James P.} and Kalra, {Philip A.} and Ritchie, {James P.} and Raman Maharajan and Helen Alderson and Beverly Lane and Eckardt, {Kai Uwe} and Schneider, {Markus P.} and Anna K{\"o}ttgen and Florian Kronenberg and Barbara B{\"a}rthlein and Chang, {Alex R.} and Green, {Jamie A.} and {Lester Kirchner}, H. and Kevin Ho and Angharad Marks and Corri Black and Prescott, {Gordon J.} and Nick Fluck and Masaaki Nakayama and Mariko Miyazaki and Tae Yamamoto and Gen Yamada and Wang, {Angela Yee Moon} and Sharon Cheung and Sharon Wong and Jessie Chu and Henry Wu and Josef Coresh and Grams, {Morgan E.} and Kunihiro Matsushita and Mark Woodward and Ballew, {Shoshana H.} and Yingying Sang and Aditya Surapaneni",

note = "Publisher Copyright: {\textcopyright} 2018 International Society of Nephrology",

year = "2018",

month = nov,

day = "1",

doi = "10.1016/j.ekir.2018.08.009",

language = "English (US)",

volume = "3",

pages = "1506",

journal = "Kidney International Reports",

issn = "2468-0249",

publisher = "Elsevier Inc.",

number = "6",

}

TY - JOUR

T1 - Erratum

T2 - Risk factors for prognosis in patients with severely decreased GFR (Kidney International Reports (2018) 3 (625-637) DOI: 10.1016/j.ekir.2018.01.002 PII: S246802491830007X)

AU - Maccabi Health System

AU - Multifactorial Approach and Superior Treatment Efficacy in Renal Patients with the Aid of a Nurse Practitioner (MASTERPLAN)

AU - Modification of Diet in Renal Disease Study (MDRD)

AU - Nanjing CKD Network Cohort Study (Nanjing CKD)

AU - NephroTest Study

AU - National RenalHealthcareProgram-Uruguay (NRHP-URU)

AU - New Zealand Diabetes Cohort Study (NZDCS)

AU - Parcours de Soins des Personnes Agées (PSPA)

AU - Primary-Secondary Care Partnership to Prevent Adverse Outcomes in Chronic Kidney Disease (PSP CKD)

AU - Racial and Cardiovascular Risk Anomalies in CKD Cohort (RCAV)

AU - Reduction of Endpoints in Non-insulin Dependent Diabetes Mellitus with the Angiotensin II Antagonist Losartan (RENAAL)

AU - Stockholm CREAtinine Measurements Cohort (SCREAM)

AU - Second Manifestations of ARTerial Disease Study (SMART)

AU - Swedish Renal Registry CKD Cohort (SRR CKD)

AU - Sunnybrook Cohort

AU - West of Scotl and CKD Study

AU - CKD Prognosis Consortium Steering Committee

AU - CKD Prognosis Consortium Data Coordinating Center

AU - Kidney Disease Improving Global Outcomes (KDIGO) Controversies Conference on Prognosis and Optimal Management of Patients with Advanced CKD

AU - Chronic Kidney Disease (CKD) Prognosis Consortium

AU - CKD Prognosis Consortium investigators/collaborators

AU - African American Study of Kidney Disease and Hypertension (AASK)

AU - British Columbia CKD Study (BC CKD)

AU - Canadian Study of Prediction of Death, Dialysis and Interim Cardiovascular Events (CanPREDDICT)

AU - Cleveland Clinic CKD Registry Study (CCF)

AU - Chronic Renal Impairment in Birmingham (CRIB)

AU - Chronic Renal Insufficiency Cohort Study (CRIC)

AU - Chronic Renal Insufficiency Standards Implementation Study (CRISIS)

AU - German Chronic Kidney Disease Study (GCKD)

AU - Geisinger Health System

AU - Grampian Laboratory Outcomes, Morbidity and Mortality Studies - 2 (GLOMMS2)

AU - Gonryo Study

AU - Hong Kong CKD Studies

AU - Astor, Brad

AU - Appel, Lawrence J.

AU - Levin, Adeera

AU - Djurdjev, Ognjenka

AU - Tang, Mila

AU - Navaneethan, Sankar D.

AU - Jolly, Stacey E.

AU - Schold, Jesse D.

AU - Nally, Joseph V.

AU - Wheeler, David C.

AU - Emberson, Jonathan

AU - Townend, John

AU - Landray, Martin

AU - Feldman, Harold I.

AU - Hsu, Chi Yuan

AU - Lash, James P.

AU - Kalra, Philip A.

AU - Ritchie, James P.

AU - Maharajan, Raman

AU - Alderson, Helen

AU - Lane, Beverly

AU - Eckardt, Kai Uwe

AU - Schneider, Markus P.

AU - Köttgen, Anna

AU - Kronenberg, Florian

AU - Bärthlein, Barbara

AU - Chang, Alex R.

AU - Green, Jamie A.

AU - Lester Kirchner, H.

AU - Ho, Kevin

AU - Marks, Angharad

AU - Black, Corri

AU - Prescott, Gordon J.

AU - Fluck, Nick

AU - Nakayama, Masaaki

AU - Miyazaki, Mariko

AU - Yamamoto, Tae

AU - Yamada, Gen

AU - Wang, Angela Yee Moon

AU - Cheung, Sharon

AU - Wong, Sharon

AU - Chu, Jessie

AU - Wu, Henry

AU - Coresh, Josef

AU - Grams, Morgan E.

AU - Matsushita, Kunihiro

AU - Woodward, Mark

AU - Ballew, Shoshana H.

AU - Sang, Yingying

AU - Surapaneni, Aditya

PY - 2018/11/1

Y1 - 2018/11/1

N2 - The Chronic Kidney Disease (CKD) Prognosis Consortium is a collaborative author of the above-mentioned article. The CKD Prognosis Consortium investigators/collaborators are as follows: • African American Study of Kidney Disease and Hypertension (AASK): Brad Astor, Lawrence J. Appel; British Columbia CKD Study (BC CKD): Adeera Levin, Ognjenka Djurdjev; Canadian Study of Prediction of Death, Dialysis and Interim Cardiovascular Events (CanPREDDICT): Adeera Levin, Mila Tang, Ognjenka Djurdjev; Cleveland Clinic CKD Registry Study (CCF): Sankar D. Navaneethan, Stacey E. Jolly, Jesse D. Schold, Joseph V. Nally Jr; Chronic Renal Impairment in Birmingham (CRIB): David C. Wheeler, Jonathan Emberson, John Townend, Martin Landray; Chronic Renal Insufficiency Cohort Study (CRIC): Harold I. Feldman, Chi-yuan Hsu, James P. Lash, Lawrence J. Appel; Chronic Renal Insufficiency Standards Implementation Study (CRISIS): Philip A. Kalra, James P. Ritchie, Raman Maharajan, Helen Alderson, Beverly Lane; German Chronic Kidney Disease Study (GCKD): Kai-Uwe Eckardt, Markus P. Schneider, Anna Köttgen, Florian Kronenberg, Barbara Bärthlein; Geisinger Health System: Alex R. Chang, Jamie A. Green, H. Lester Kirchner, Kevin Ho; Grampian Laboratory Outcomes, Morbidity and Mortality Studies – 2 (GLOMMS2): Angharad Marks, Corri Black, Gordon J. Prescott, Nick Fluck; Gonryo Study: Masaaki Nakayama, Mariko Miyazaki, Tae Yamamoto, Gen Yamada; Hong Kong CKD Studies: Angela Yee-Moon Wang, Sharon Cheung, Sharon Wong, Jessie Chu, Henry Wu; Maccabi Health System: Varda Shalev, Gabriel Chodick; Multifactorial Approach and Superior Treatment Efficacy in Renal Patients with the Aid of a Nurse Practitioner (MASTERPLAN): Peter J. Blankestijn, Jack F.M. Wetzels, Arjan D. van Zuilen, Jan A. van den Brand; Modification of Diet in Renal Disease Study (MDRD): Andrew S. Levey, Lesley A. Inker, Mark J. Sarnak, Hocine Tighiouart; Nanjing CKD Network Cohort Study (Nanjing CKD): Haitao Zhang; NephroTest Study: Benedicte Stengel; National Renal Healthcare Program – Uruguay (NRHP-URU): Pablo G. Rios, Nelson Mazzuchi, Liliana Gadola, Verónica Lamadrid, Laura Sola; New Zealand Diabetes Cohort Study (NZDCS): John F. Collins, C. Raina Elley, Timothy Kenealy; Parcours de Soins des Personnes Agées (PSPA): Olivier Moranne, Cecile Couchoud, Cecile Vigneau; Primary-Secondary Care Partnership to Prevent Adverse Outcomes in Chronic Kidney Disease (PSP CKD): Nigel J. Brunskill, Rupert W. Major, David Shepherd, James F. Medcalf; Racial and Cardiovascular Risk Anomalies in CKD Cohort (RCAV): Csaba P. Kovesdy, Kamyar Kalantar-Zadeh, Miklos Z. Molnar, Keiichi Sumida, Praveen K. Potukuchi; Reduction of Endpoints in Non-insulin Dependent Diabetes Mellitus with the Angiotensin II Antagonist Losartan (RENAAL): Hiddo J.L. Heerspink, Dick de Zeeuw, Barry Brenner; Stockholm CREAtinine Measurements Cohort (SCREAM): Juan Jesus Carrero, Peter Barany, Abdul Rashid Qureshi, Carl-Gustaf Elinder; Second Manifestations of ARTerial Disease Study (SMART): Frank L.J. Visseren, Yolanda van der Graaf; Swedish Renal Registry CKD Cohort (SRR CKD): Marie Evans, Maria Stendahl, Staffan Schön, Mårten Segelmark, Karl-Göran Prütz; Sunnybrook Cohort: David M. Naimark, Navdeep Tangri; West of Scotland CKD Study: Patrick B. Mark, Jamie P. Traynor, Colin C. Geddes, Peter C. Thomson.• CKD Prognosis Consortium Steering Committee: Alex R. Chang, Josef Coresh (Chair), Ron T. Gansevoort, Morgan E. Grams, Anna Köttgen, Andrew S. Levey, Kunihiro Matsushita, Mark Woodward, Luxia Zhang.• CKD Prognosis Consortium Data Coordinating Center: Shoshana H. Ballew (Assistant Project Director), Jingsha Chen (Programmer), Josef Coresh (Principal Investigator), Morgan E. Grams (Director of Nephrology Initiatives), Lucia Kwak (Programmer), Kunihiro Matsushita (Director), Yingying Sang (Lead Programmer), Aditya Surapaneni (Programmer), Mark Woodward (Senior Statistician).• Kidney Disease Improving Global Outcomes (KDIGO) Controversies Conference on Prognosis and Optimal Management of Patients with Advanced CKD: Kai-Uwe Eckardt (Conference Co-Chair), Brenda R. Hemmelgarn (Conference Co-Chair), David C. Wheeler (KDIGO Co-Chair), Wolfgang C. Winkelmayer (KDIGO Co-Chair), John Davis (CEO), Danielle Green (Managing Director), Michael Cheung (Chief Scientific Officer), Tanya Green (Communications Director), Melissa McMahan (Programs Director).

AB - The Chronic Kidney Disease (CKD) Prognosis Consortium is a collaborative author of the above-mentioned article. The CKD Prognosis Consortium investigators/collaborators are as follows: • African American Study of Kidney Disease and Hypertension (AASK): Brad Astor, Lawrence J. Appel; British Columbia CKD Study (BC CKD): Adeera Levin, Ognjenka Djurdjev; Canadian Study of Prediction of Death, Dialysis and Interim Cardiovascular Events (CanPREDDICT): Adeera Levin, Mila Tang, Ognjenka Djurdjev; Cleveland Clinic CKD Registry Study (CCF): Sankar D. Navaneethan, Stacey E. Jolly, Jesse D. Schold, Joseph V. Nally Jr; Chronic Renal Impairment in Birmingham (CRIB): David C. Wheeler, Jonathan Emberson, John Townend, Martin Landray; Chronic Renal Insufficiency Cohort Study (CRIC): Harold I. Feldman, Chi-yuan Hsu, James P. Lash, Lawrence J. Appel; Chronic Renal Insufficiency Standards Implementation Study (CRISIS): Philip A. Kalra, James P. Ritchie, Raman Maharajan, Helen Alderson, Beverly Lane; German Chronic Kidney Disease Study (GCKD): Kai-Uwe Eckardt, Markus P. Schneider, Anna Köttgen, Florian Kronenberg, Barbara Bärthlein; Geisinger Health System: Alex R. Chang, Jamie A. Green, H. Lester Kirchner, Kevin Ho; Grampian Laboratory Outcomes, Morbidity and Mortality Studies – 2 (GLOMMS2): Angharad Marks, Corri Black, Gordon J. Prescott, Nick Fluck; Gonryo Study: Masaaki Nakayama, Mariko Miyazaki, Tae Yamamoto, Gen Yamada; Hong Kong CKD Studies: Angela Yee-Moon Wang, Sharon Cheung, Sharon Wong, Jessie Chu, Henry Wu; Maccabi Health System: Varda Shalev, Gabriel Chodick; Multifactorial Approach and Superior Treatment Efficacy in Renal Patients with the Aid of a Nurse Practitioner (MASTERPLAN): Peter J. Blankestijn, Jack F.M. Wetzels, Arjan D. van Zuilen, Jan A. van den Brand; Modification of Diet in Renal Disease Study (MDRD): Andrew S. Levey, Lesley A. Inker, Mark J. Sarnak, Hocine Tighiouart; Nanjing CKD Network Cohort Study (Nanjing CKD): Haitao Zhang; NephroTest Study: Benedicte Stengel; National Renal Healthcare Program – Uruguay (NRHP-URU): Pablo G. Rios, Nelson Mazzuchi, Liliana Gadola, Verónica Lamadrid, Laura Sola; New Zealand Diabetes Cohort Study (NZDCS): John F. Collins, C. Raina Elley, Timothy Kenealy; Parcours de Soins des Personnes Agées (PSPA): Olivier Moranne, Cecile Couchoud, Cecile Vigneau; Primary-Secondary Care Partnership to Prevent Adverse Outcomes in Chronic Kidney Disease (PSP CKD): Nigel J. Brunskill, Rupert W. Major, David Shepherd, James F. Medcalf; Racial and Cardiovascular Risk Anomalies in CKD Cohort (RCAV): Csaba P. Kovesdy, Kamyar Kalantar-Zadeh, Miklos Z. Molnar, Keiichi Sumida, Praveen K. Potukuchi; Reduction of Endpoints in Non-insulin Dependent Diabetes Mellitus with the Angiotensin II Antagonist Losartan (RENAAL): Hiddo J.L. Heerspink, Dick de Zeeuw, Barry Brenner; Stockholm CREAtinine Measurements Cohort (SCREAM): Juan Jesus Carrero, Peter Barany, Abdul Rashid Qureshi, Carl-Gustaf Elinder; Second Manifestations of ARTerial Disease Study (SMART): Frank L.J. Visseren, Yolanda van der Graaf; Swedish Renal Registry CKD Cohort (SRR CKD): Marie Evans, Maria Stendahl, Staffan Schön, Mårten Segelmark, Karl-Göran Prütz; Sunnybrook Cohort: David M. Naimark, Navdeep Tangri; West of Scotland CKD Study: Patrick B. Mark, Jamie P. Traynor, Colin C. Geddes, Peter C. Thomson.• CKD Prognosis Consortium Steering Committee: Alex R. Chang, Josef Coresh (Chair), Ron T. Gansevoort, Morgan E. Grams, Anna Köttgen, Andrew S. Levey, Kunihiro Matsushita, Mark Woodward, Luxia Zhang.• CKD Prognosis Consortium Data Coordinating Center: Shoshana H. Ballew (Assistant Project Director), Jingsha Chen (Programmer), Josef Coresh (Principal Investigator), Morgan E. Grams (Director of Nephrology Initiatives), Lucia Kwak (Programmer), Kunihiro Matsushita (Director), Yingying Sang (Lead Programmer), Aditya Surapaneni (Programmer), Mark Woodward (Senior Statistician).• Kidney Disease Improving Global Outcomes (KDIGO) Controversies Conference on Prognosis and Optimal Management of Patients with Advanced CKD: Kai-Uwe Eckardt (Conference Co-Chair), Brenda R. Hemmelgarn (Conference Co-Chair), David C. Wheeler (KDIGO Co-Chair), Wolfgang C. Winkelmayer (KDIGO Co-Chair), John Davis (CEO), Danielle Green (Managing Director), Michael Cheung (Chief Scientific Officer), Tanya Green (Communications Director), Melissa McMahan (Programs Director).

UR - http://www.scopus.com/inward/record.url?scp=85055632612&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055632612&partnerID=8YFLogxK

U2 - 10.1016/j.ekir.2018.08.009

DO - 10.1016/j.ekir.2018.08.009

M3 - Comment/debate

C2 - 30450480

AN - SCOPUS:85055632612

SN - 2468-0249

VL - 3

SP - 1506

JO - Kidney International Reports

JF - Kidney International Reports

IS - 6

ER -

Erratum: Risk factors for prognosis in patients with severely decreased GFR (Kidney International Reports (2018) 3 (625-637) DOI: 10.1016/j.ekir.2018.01.002 PII: S246802491830007X)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this